Get the Stockscreener App
54.32
2.74%
-1.5295
Cg Oncology Inc stock is traded at $54.32, with a volume of 408.71K.
It is down -2.74% in the last 24 hours and up +35.63% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$55.85
Open:
$54.76
24h Volume:
408.71K
Relative Volume:
0.39
Market Cap:
$4.48B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-42.77
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
-0.75%
1M Performance:
+35.63%
6M Performance:
+106.38%
1Y Performance:
+76.65%
1-Day Range:
$53.94
$55.44
1-Week Range:
$52.51
$57.88
52-Week Range:
$14.80
$57.88
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
54.24 | 4.61B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.64 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
817.00 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.53 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
Bladder Cancer Vaccines Market Poised for Rapid Growth at 21.32% - openPR.com
CG Oncology stock hits all-time high at 57.4 USD By Investing.com - Investing.com Nigeria
CG Oncology (NASDAQ:CGON) Sets New 52-Week HighShould You Buy? - MarketBeat
What Analysts Are Saying About CG Oncology Stock - Benzinga
CGON: RBC Capital Raises Price Target to $73, Maintains Outperfo - GuruFocus
CG Oncology stock hits all-time high at 57.4 USD - Investing.com
Portfolio Shifts: Can CG Oncology Inc expand into new marketsQuarterly Trade Review & Consistent Income Trade Recommendations - baoquankhu1.vn
Profit Review: What are CG Oncology Incs earnings expectationsChart Signals & Fast Moving Trade Plans - baoquankhu1.vn
Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline - Sahm
Investment Review: Can CG Oncology Inc sustain earnings growthEarnings Performance Report & High Win Rate Trade Tips - baoquankhu1.vn
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Revenue Check: Is CG Oncology Inc stock a hidden gemRate Hike & Risk Managed Investment Signals - baoquankhu1.vn
Gainers Report: Is Citigroup Capital XVI Preferred Security stock undervalued right nowEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
CGON: Pivotal data and regulatory milestones position a novel NMIBC therapy for major market expansion - TradingView — Track All Markets
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
CG Oncology Expands At-The-Market Equity Offering Capacity - The Globe and Mail
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026 - Intellectia AI
Why CG Oncology Stock Is Suddenly Climbing Higher - TipRanks
Oncolytics Biotech Inc. Appoints John McAdory as Executive Vice President of Strategy and Operations - marketscreener.com
Travel Stocks: What is the target price for CG Oncology Inc stock2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com - Investing.com Australia
Aug Highlights: Will CG Oncology Inc outperform the market in YEARPortfolio Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Mulay, James sells CG Oncology (CGON) shares for $584,798 - Investing.com
CG Oncology files amendment to increase stock offering to $550 million By Investing.com - Investing.com Nigeria
James Mulay Sells 11,145 Shares of CG Oncology (NASDAQ:CGON) Stock - MarketBeat
CG Oncology files amendment to increase stock offering to $550 million - Investing.com
CG Oncology Files Amendment to Increase Stock Offering - TradingView — Track All Markets
Aug Spikes: Is Skeena Resources Limited attractive for institutional investorsDollar Strength & Weekly Top Stock Performers List - baoquankhu1.vn
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates - MSN
Institution Moves: Why analysts upgrade CG Oncology Inc. stockJuly 2025 Fed Impact & AI Enhanced Trading Signals - Bộ Nội Vụ
Truist Securities raises CG Oncology stock price target to $66 on early trial data - Investing.com Canada
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Sahm
CG Oncology Expedites PIVOT-006 Phase 3 Topline Data Readout In Intermediate-Risk NMIBC To H1 2026 - Nasdaq
CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week - TechStock²
CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next - TechStock²
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next - TechStock²
Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum - Sahm
CG Oncology accelerates timeline for bladder cancer trial data By Investing.com - Investing.com Nigeria
Cg Oncology stock hits 52-week high at 46.19 USD By Investing.com - Investing.com Nigeria
Is CG Oncology Inc. stock supported by strong cash flowsJuly 2025 Setups & High Accuracy Swing Trade Signals - ulpravda.ru
CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 TimelineHas The Bull Case Changed? - Yahoo Finance
Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? - Yahoo Finance
CG Oncology’s Bladder Cancer Bet Heads Toward A Big 2026 Test - Finimize
Accelerated PIVOT-006 Timeline and Expanded NMIBC Opportunity Drive CG Oncology Target Hike to $108 and Reinforce Buy Rating - TipRanks
CG Oncology Gains Momentum as Price Targets and Investor Confidence Rise - StocksToTrade
CG Oncology Price Target Raised Amid Robust Market Prospects - timothysykes.com
CG Oncology stock price target raised to $93 from $89 at Morgan Stanley - Investing.com Canada
Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology - TipRanks
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):